Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma

Next Previous
Trial Profile

Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary) ; Entinostat (Primary) ; Fludeoxyglucose F-18
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 Mar 2025 Planned End Date changed from 30 Jul 2025 to 12 Feb 2026.
  • 03 Mar 2025 Planned End Date changed from 30 Jul 2025 to 12 Feb 2026.
  • 27 Aug 2024 Planned End Date changed from 17 Jul 2024 to 30 Jul 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top